1 November 2023 false Taxfiler 2024.6 15253317business:PrivateLimitedCompanyLtd2023-11-012024-11-30 152533172023-10-31 152533172023-11-012024-11-30 15253317business:AuditExempt-NoAccountantsReport2023-11-012024-11-30 15253317business:FilletedAccounts2023-11-012024-11-30 152533172024-11-30 15253317business:Director22023-11-012024-11-30 15253317business:Director32023-11-012024-11-30 15253317business:Director42023-11-012024-11-30 15253317business:RegisteredOffice2023-11-012024-11-30 15253317core:WithinOneYear2024-11-30 15253317core:AfterOneYear2024-11-30 15253317core:ShareCapitalcore:PreviouslyStatedAmount2024-11-30 15253317core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-11-30 15253317core:PreviouslyStatedAmount2024-11-30 15253317business:SmallEntities2023-11-012024-11-30 15253317countries:EnglandWales2023-11-012024-11-30 15253317core:FurnitureFittings2023-11-012024-11-30 15253317core:Goodwill2023-10-31 15253317core:Goodwill2023-11-012024-11-30 15253317core:Goodwill2024-11-30 15253317core:FurnitureFittings2023-10-31 15253317core:FurnitureFittings2024-11-30 iso4217:GBP xbrli:pure
Company Registration No. 15253317 (England and Wales)
Thorpe Pharma Ltd Unaudited accounts for the period from 1 November 2023 to 30 November 2024
Thorpe Pharma Ltd Unaudited accounts Contents
Page
- 2 -
Thorpe Pharma Ltd Company Information for the period from 1 November 2023 to 30 November 2024
Directors
Muhammad Umair Zafar Mohammed Riaz Kauser Ayesha Hafeez
Company Number
15253317 (England and Wales)
Registered Office
22 Glen Drive Boston Lincolnshire PE21 7QB England
- 3 -
Thorpe Pharma Ltd Statement of financial position as at 30 November 2024
2024 
Notes
£ 
Fixed assets
Intangible assets
325,000 
Tangible assets
19,400 
344,400 
Current assets
Inventories
43,409 
Debtors
27,456 
Cash at bank and in hand
47,421 
118,286 
Creditors: amounts falling due within one year
(55,758)
Net current assets
62,528 
Total assets less current liabilities
406,928 
Creditors: amounts falling due after more than one year
(405,000)
Net assets
1,928 
Capital and reserves
Called up share capital
1 
Profit and loss account
1,927 
Shareholders' funds
1,928 
For the period ending 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board of Directors and authorised for issue on 11 July 2025 and were signed on its behalf by
Muhammad Umair Zafar Director Company Registration No. 15253317
- 4 -
Thorpe Pharma Ltd Notes to the Accounts for the period from 1 November 2023 to 30 November 2024
1
Statutory information
Thorpe Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 15253317. The registered office is 22 Glen Drive, Boston, Lincolnshire, PE21 7QB, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
18%
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
4
Intangible fixed assets
Goodwill 
£ 
Cost
At 1 November 2023
- 
Additions
325,000 
At 30 November 2024
325,000 
Amortisation
At 1 November 2023
- 
At 30 November 2024
- 
Net book value
At 30 November 2024
325,000 
- 5 -
Thorpe Pharma Ltd Notes to the Accounts for the period from 1 November 2023 to 30 November 2024
5
Tangible fixed assets
Fixtures & fittings 
£ 
Cost or valuation
At cost 
At 1 November 2023
- 
Additions
20,000 
At 30 November 2024
20,000 
Depreciation
Charge for the period
600 
At 30 November 2024
600 
Net book value
At 30 November 2024
19,400 
6
Debtors
2024 
£ 
Amounts falling due within one year
VAT
14,206 
Accrued income and prepayments
13,250 
27,456 
7
Creditors: amounts falling due within one year
2024 
£ 
Trade creditors
55,106 
Taxes and social security
452 
Other creditors
200 
55,758 
8
Creditors: amounts falling due after more than one year
2024 
£ 
Loans from directors
405,000 
9
Average number of employees
During the period the average number of employees was 0.
- 6 -